ABSTRACT
The pharmacokinetics of fluvoxamine maleate was studied in two separate studies in healthy young and elderly subjects. In a single and multiple oral dose administration study, six healthy young subjects received an initial 50 mg oral dose followed by 50 mg tablets every 12 h for 28 days. In a second study, 13 elderly subjects received 50 mg tablets every 12 h for 28 days. Fluvoxamine peak plasma concentrations were reached in approximately 5-6 h following oral administration of single and multiple 50 mg doses to healthy young and elderly volunteers. The area under the curve (AUC) of fluvoxamine tended to be larger following multiple (873 ng.h/ml) as compared to single-dose administration (652 ng.h/ml). Also the terminal half-life after chronic dosing (22 +/- 6 h) tended to be longer than after single dosing. Steady-state plasma levels were obtained within 10 days' administration. The pharmacokinetics of fluvoxamine in elderly healthy subjects were no different from those recorded in young subjects. These results suggest that it is not necessary to adjust the dosage of fluvoxamine in elderly depressed patients, on the basis of pharmacokinetic arguments. Independent of the age group, approximately 3% of a dose was recovered as unchanged drug in the urine.
Subject(s)
Aging/metabolism , Fluvoxamine/pharmacokinetics , Administration, Oral , Adult , Aged , Drug Administration Schedule , Female , Fluvoxamine/administration & dosage , Fluvoxamine/adverse effects , Humans , Male , Middle Aged , Reference ValuesABSTRACT
The pharmacokinetics of eltoprazine in healthy male subjects was investigated after intravenous and oral dosing in one study, and after oral dosing of 14C-eltoprazine in a second study. It was shown that the absorption of eltoprazine from the gastro-intestinal tract was complete, and that absolute bioavailability was 100%. The mean elimination half-life of eltoprazine in plasma was about 8 hours. Approximately 40% of the dose was excreted unchanged in urine.
